BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32951717)

  • 41. [Clinical study on survival benefit for elderly patients with resected stage II or III colorectal cancer based on traditional Chinese medicine syndrome differentiation and treatment].
    Tao L; Zhu YJ; Lu XM; Gu Y; Zhao AG; Zheng J; Fu CG; Yang JK
    Zhong Xi Yi Jie He Xue Bao; 2010 Dec; 8(12):1159-64. PubMed ID: 21144459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study.
    Lee YW; Chen TL; Shih YR; Tsai CL; Chang CC; Liang HH; Tseng SH; Chien SC; Wang CC
    Cancer; 2014 May; 120(9):1338-44. PubMed ID: 24496917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Safety of breast-conserving treatment for triple-negative breast cancer].
    Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
    Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
    Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (≥60) patients.
    Qiu JD; Xue XY; Li R; Wang JD
    Eur J Cancer Care (Engl); 2016 Nov; 25(6):1065-1075. PubMed ID: 26122025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study.
    Shi Q; Liu S; Li W; Zong S; Han S; Yang W; Li H; Hou F
    Oncotarget; 2017 Feb; 8(8):13488-13495. PubMed ID: 28086238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
    Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
    J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Factor analysis of diagnosis and surgical treatment of local regional recurrence in breast cancer patients].
    Jin ZY; Lu YJ; Chen WG; Li YF; Chen XS; Shen KW
    Zhonghua Wai Ke Za Zhi; 2019 May; 57(5):366-372. PubMed ID: 31091592
    [No Abstract]   [Full Text] [Related]  

  • 56. Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
    Khalifa J; Duprez-Paumier R; Filleron T; Lacroix Triki M; Jouve E; Dalenc F; Massabeau C
    Breast J; 2016 Sep; 22(5):510-9. PubMed ID: 27261365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiation treatment in early stage triple-negative breast cancer in New Zealand: A national database study.
    Dixit A; Frampton C; Davey V; Robinson B; James M
    J Med Imaging Radiat Oncol; 2019 Oct; 63(5):698-706. PubMed ID: 31368670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
    Cui J; Jiang H
    Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.